Early <sup>18</sup>F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence.
dc.contributor.author | Mowery, Yvonne M | |
dc.contributor.author | Vergalasova, Irina | |
dc.contributor.author | Rushing, Christel N | |
dc.contributor.author | Choudhury, Kingshuk Roy | |
dc.contributor.author | Niedzwiecki, Donna | |
dc.contributor.author | Wu, Qiuwen | |
dc.contributor.author | Yoo, David S | |
dc.contributor.author | Das, Shiva | |
dc.contributor.author | Wong, Terence Z | |
dc.contributor.author | Brizel, David M | |
dc.date.accessioned | 2022-01-01T15:04:30Z | |
dc.date.available | 2022-01-01T15:04:30Z | |
dc.date.issued | 2020-11 | |
dc.date.updated | 2022-01-01T15:04:30Z | |
dc.description.abstract | PurposeEarly indication of treatment outcome may guide therapeutic de-escalation strategies in patients with human papillomavirus (HPV)-related oropharyngeal cancer (OPC). This study investigated the relationships between tumor volume and 18F-fluorodeoxyglucose positron emission tomography (PET) parameters before and during definitive radiation therapy with treatment outcomes.Methods and materialsPatients undergoing definitive (chemo)radiation for HPV-related/p16-positive OPC were prospectively enrolled on an institutional review board-approved study. 18F-fluorodeoxyglucose PET/computed tomography scans were performed at simulation and after 2 weeks at a dose of ∼20 Gy. Tumor volume and standardized uptake value (SUV) characteristics were measured. SUV was normalized to blood pool uptake. Tumor volume and PET parameters associated with recurrence were identified through recursive partitioning (RPART). Recurrence-free survival (RFS) and overall survival (OS) curves between RPART-identified cohorts were estimated using the Kaplan-Meier method, and Cox models were used to estimate the hazard ratios (HRs).ResultsFrom 2012 to 2016, 62 patients with HPV-related OPC were enrolled. Median follow-up was 4.4 years. RPART identified patients with intratreatment SUVmax (normalized to blood pool SUVmean) <6.7 or SUVmax (normalized to blood pool SUVmean) ≥6.7 with intratreatment SUV40% ≥2.75 as less likely to recur. For identified subgroups, results of Cox models showed unadjusted HRs for RFS and OS (more likely to recur vs less likely) of 7.33 (90% confidence interval [CI], 2.97-18.12) and 6.09 (90% CI, 2.22-16.71), respectively, and adjusted HRs of 6.57 (90% CI, 2.53-17.05) and 5.61 (90% CI, 1.90-16.54) for RFS and OS, respectively.ConclusionsPET parameters after 2 weeks of definitive radiation therapy for HPV-related OPC are associated with RFS and OS, thus potentially informing an adaptive treatment approach. | |
dc.identifier | S0360-3016(20)34118-3 | |
dc.identifier.issn | 0360-3016 | |
dc.identifier.issn | 1879-355X | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Elsevier BV | |
dc.relation.ispartof | International journal of radiation oncology, biology, physics | |
dc.relation.isversionof | 10.1016/j.ijrobp.2020.08.029 | |
dc.subject | Humans | |
dc.subject | Papillomavirus Infections | |
dc.subject | Oropharyngeal Neoplasms | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Cisplatin | |
dc.subject | Fluorodeoxyglucose F18 | |
dc.subject | Antineoplastic Agents | |
dc.subject | Radiopharmaceuticals | |
dc.subject | Treatment Outcome | |
dc.subject | Tumor Burden | |
dc.subject | Analysis of Variance | |
dc.subject | Proportional Hazards Models | |
dc.subject | Prospective Studies | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Human papillomavirus 16 | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.subject | Docetaxel | |
dc.title | Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. | |
dc.type | Journal article | |
duke.contributor.orcid | Mowery, Yvonne M|0000-0002-9839-2414 | |
duke.contributor.orcid | Niedzwiecki, Donna|0000-0002-3566-0450 | |
duke.contributor.orcid | Wu, Qiuwen|0000-0003-0748-7280 | |
duke.contributor.orcid | Wong, Terence Z|0000-0002-1435-3187|0000-0002-3830-1779 | |
pubs.begin-page | 969 | |
pubs.end-page | 976 | |
pubs.issue | 4 | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Radiology, Nuclear Medicine | |
pubs.organisational-group | Medicine, Medical Oncology | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Radiology | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Faculty | |
pubs.organisational-group | Radiation Oncology | |
pubs.organisational-group | Head and Neck Surgery & Communication Sciences | |
pubs.organisational-group | Biostatistics & Bioinformatics | |
pubs.organisational-group | Basic Science Departments | |
pubs.publication-status | Published | |
pubs.volume | 108 |
Files
Original bundle
- Name:
- 1-s2.0-S0022522305013954-main.pdf
- Size:
- 189.29 KB
- Format:
- Adobe Portable Document Format